Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Zanotti

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Calcified Tissue International|October 16, 2016
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without OsteoporosisA Artuso, C Caimmi, G Tripi, et al.
Leukemia|March 1, 1994
Relationship between Daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemiaG Todeschini, V Meneghini, G Pizzolo, et al.
International Journal of Oncology|May 5, 2011
Primary extranodal lymphomas of Waldeyer's ring, stage IE and IIEF Pasini, M Bassetto, G Todeschini, et al.
Leukemia|March 1, 1993
Alpha (p55) and beta (p75) chains of the interleukin-2 receptor are expressed by AML blastsG Pizzolo, A Rigo, R Zanotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosisG Nadali, F Vinante, A Ambrosetti, et al.
Cancer|November 15, 1989
Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytesR Zambello, G Pizzolo, L Trentin, et al.
Leukemia|March 31, 1998
Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicinG Todeschini, C Tecchio, V Meneghini, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 20, 2016
Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosisM Rossini, R Zanotti, G Orsolini, et al.
Oncology|January 1, 1991
The antiemetic activity of high-dose metoclopramide and high-dose alizapride in combination with lorazepam in patients receiving cancer chemotherapy. A prospective, randomized, double-blind studyA Molino, L Guglielmo, M E Azzolini, et al.
British Journal of Haematology|September 1, 1996
In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosisD Gottardi, A Alfarano, A M De Leo, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Calcified Tissue International|October 16, 2016
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without OsteoporosisA Artuso, C Caimmi, G Tripi, et al.
Leukemia|March 1, 1994
Relationship between Daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemiaG Todeschini, V Meneghini, G Pizzolo, et al.
International Journal of Oncology|May 5, 2011
Primary extranodal lymphomas of Waldeyer's ring, stage IE and IIEF Pasini, M Bassetto, G Todeschini, et al.
Leukemia|March 1, 1993
Alpha (p55) and beta (p75) chains of the interleukin-2 receptor are expressed by AML blastsG Pizzolo, A Rigo, R Zanotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosisG Nadali, F Vinante, A Ambrosetti, et al.
Cancer|November 15, 1989
Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytesR Zambello, G Pizzolo, L Trentin, et al.
Leukemia|March 31, 1998
Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicinG Todeschini, C Tecchio, V Meneghini, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 20, 2016
Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosisM Rossini, R Zanotti, G Orsolini, et al.
Oncology|January 1, 1991
The antiemetic activity of high-dose metoclopramide and high-dose alizapride in combination with lorazepam in patients receiving cancer chemotherapy. A prospective, randomized, double-blind studyA Molino, L Guglielmo, M E Azzolini, et al.
British Journal of Haematology|September 1, 1996
In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosisD Gottardi, A Alfarano, A M De Leo, et al.
Pageof 5